These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15799443)

  • 1. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A; Kamatani N
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice.
    Taniguchi A; Urano W; Tanaka E; Furihata S; Kamitsuji S; Inoue E; Yamanaka M; Yamanaka H; Kamatani N
    Pharmacogenet Genomics; 2007 Jun; 17(6):383-90. PubMed ID: 17502830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacogenetics of disease modifying anti-rheumatic drugs].
    Taniguchi A; Urano W; Tanaka E; Akama H; Yamanaka H; Kamatani N
    Nihon Rinsho; 2002 Dec; 60(12):2339-44. PubMed ID: 12510359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race and methotrexate pharmacogenetics in rheumatoid arthritis.
    Ranganathan P; McLeod H
    J Rheumatol; 2010 May; 37(5):1064; author reply 1065. PubMed ID: 20439524
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T
    J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond.
    Kooloos WM; Wessels JA; van der Kooij SM; Allaart CF; Huizinga TW; Guchelaar HJ
    Ann Rheum Dis; 2009 Aug; 68(8):1371. PubMed ID: 19605746
    [No Abstract]   [Full Text] [Related]  

  • 8. Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis.
    Soejima M; Kawaguchi Y; Hara M; Kamatani N
    J Rheumatol; 2008 Apr; 35(4):724. PubMed ID: 18398952
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
    Taniguchi A; Urano W; Tanaka E; Kamatani N
    Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacogenomics of the immunosuppressive agents].
    Taniguchi A; Urano W; Tanaka E; Kitamura Y; Saito M; Akama H; Yamanak H; Saito T; Kamatani N
    Nihon Rinsho Meneki Gakkai Kaishi; 2002 Feb; 25(1):105-9. PubMed ID: 11963167
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al.
    Ranganathan P
    Arthritis Rheum; 2006 Oct; 54(10):3372; author reply 3372-3. PubMed ID: 17009311
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rheumatoid arthritis.
    Zurier RB; DeMarco DM; Liu NY
    N Engl J Med; 1996 Sep; 335(11):822; author reply 822-3. PubMed ID: 8778595
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of rheumatoid arthritis.
    Stohl W; Arkfeld DG
    N Engl J Med; 1996 Sep; 335(11):821-2; author reply 822-3. PubMed ID: 8778593
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.
    Shiroky JB
    J Rheumatol Suppl; 1996 Mar; 44():69-71. PubMed ID: 8833057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 2)].
    Swierkot J; Slęzak R
    Postepy Hig Med Dosw (Online); 2011 Mar; 65():207-15. PubMed ID: 21502697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.
    Owen SA; Lunt M; Hider SL; Bruce IN; Barton A; Thomson W
    Arthritis Rheum; 2010 Dec; 62(12):3827-9. PubMed ID: 20848569
    [No Abstract]   [Full Text] [Related]  

  • 19. Methotrexate pharmacogenomics.
    Kremer JM
    Ann Rheum Dis; 2006 Sep; 65(9):1121-3. PubMed ID: 16905578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.